Infinity Pharmaceuticals Inc.  

(Public, NASDAQ:INFI)   Watch this stock  
Find more results for INFI
11.84
+0.45 (3.95%)
Jul 11 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 11.29 - 11.96
52 week 8.40 - 23.68
Open 11.40
Vol / Avg. 332,423.00/429,154.00
Mkt cap 574.74M
P/E     -
Div/yield     -
EPS -2.94
Shares 48.54M
Beta 1.19
Inst. own 101%
Aug 4, 2014
Q2 2014 Infinity Pharmaceuticals, Inc. Earnings Release (Estimated) Add to calendar
Jun 24, 2014
Infinity Pharmaceuticals, Inc. at JMP Securities Healthcare Conference
Jun 18, 2014
Infinity Pharmaceuticals, Inc. at Wells Fargo Healthcare Conference
Jun 17, 2014
Infinity Pharmaceuticals, Inc. Annual Shareholder Meeting
Jun 10, 2014
Infinity Pharmaceuticals, Inc. at Goldman Sachs Healthcare Conference - Webcast
Jun 3, 2014
Infinity Pharmaceuticals, Inc. at Jefferies Global Healthcare Conference - Webcast
May 21, 2014
Infinity Pharmaceuticals, Inc. at UBS Global Healthcare Conference - Webcast
May 13, 2014
Infinity Pharmaceuticals, Inc. at Bank of America Merrill Lynch Health Care Conference - Webcast
May 7, 2014
Infinity Pharmaceuticals, Inc. at Deutsche Bank Healthcare Conference - Webcast
May 6, 2014
Q1 2014 Infinity Pharmaceuticals, Inc. Earnings Conference Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -78.76% -44.77%
Return on average equity -90.58% -49.57%
Employees 151 -
CDP Score - -

Address

780 Memorial Drive
CAMBRIDGE, MA 02139
United States - Map
+1-617-4531000 (Phone)
+1-617-4531001 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Infinity Pharmaceuticals, Inc. (IPI) is a drug discovery and development company. The Company's lead product is a potent, oral inhibitor of Class I PI3K-delta and PI3K-gamma, which the Company is investigating in both hematologic malignancies and inflammatory diseases.Its retaspimycin hydrochloride (HCl), is a potent and selective inhibitor of heat shock protein 90 (Hsp90). The phosphoinositide-3-kinases (PI3Ks) are key cellular signaling proteins that act as a central node for relaying signals from cell surface receptors to downstream biochemical events. The Company�s lead development candidate in this program is IPI-145 a potent, oral inhibitor of Class I PI3K-delta,gamma for which clinical trials are conducted form both hematologic malignancies and inflammatory diseases. Hematologic malignancies are cancers of the blood or bone marrow and include leukemia and lymphoma, such as chronic lymphocytic leukemia (CLL), Hodgkin lymphoma, and non-Hodgkin lymphoma (NHL).

Officers and directors

Adelene Q. Perkins Chairman of the Board, President, Chief Executive Officer
Age: 54
Bio & Compensation  - Reuters
Lawrence E. Bloch M.D., J.D. Chief Financial Officer, Executive Vice President, Chief Business Officer
Age: 49
Bio & Compensation  - Reuters
Julian Adams Ph.D. President - Research & Development
Age: 59
Bio & Compensation  - Reuters
Vito J. Palombella Ph.D. Chief Scientific Officer
Age: 51
Bio & Compensation  - Reuters
David A. Roth M.D. Chief Medical Officer
Age: 51
Bio & Compensation  - Reuters
Norman C. Selby Lead Outside Independent Director
Age: 62
Bio & Compensation  - Reuters
Jose Baselga M.D., Ph.D. Independent Director
Age: 54
Bio & Compensation  - Reuters
Jeffrey Berkowitz J.D. Independent Director
Age: 48
Bio & Compensation  - Reuters
Anthony B. Evnin Ph.D. Independent Director
Age: 73
Bio & Compensation  - Reuters
Gwendolyn A. Fyfe M.D. Independent Director
Age: 62
Bio & Compensation  - Reuters